Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug198 | Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C Wiki | 1.00 |
drug200 | Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
In December 2019, coronavirus pneumonia (COVID-19) was detected in many cases in Wuhan, China. With the rapid spread of the coronavirus, cases of COVID-19 were also reported in other cities of China and other countries. COVID-19 can cause amplification of the pulmonary inflammatory responses, including the production of a large amount of free radicals and the release of inflammatory factors, in a short time after infection, leading to lung tissue damage and dysfunction, even resulting in life-threatening respiratory distress syndrome and respiratory failure. At present, there are no effective drugs targeting COVID-19. Previous studies have shown that Buzhong Yiqi Decoction has anti-bacterial, anti-viral, and anti-allergy effects. High-dose vitamin C also has anti-oxidative and anti-toxin effects, possibly exhibiting good effects in the treatment of viral infection and critical respiratory diseases. The study objectives include (1) investigate whether Buzhong Yiqi Decoction can improve the clinical symptoms of patients with mild and severe COVID-19 and accelerate recovery and to further investigate the clinical efficacy of high-dose vitamin C combined with traditional Chinese medicine in the treatment of mild and severe COVID-19; (2) to assess the safety of high-dose vitamin C combined with Chinese medicine in the treatment of mild and severe COVID-19.
Description: The discharge criteria of Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) are applied: a) body temperature is back to normal for more than three days; b) respiratory symptoms improve obviously; c) pulmonary imaging shows obvious resolution of inflammation; d) nuclei acid tests negative twice consecutively on respiratory tract samples such as sputum and nasopharyngeal swabs (sampling interval being at least 24 hours)
Measure: Recovery time Time: From date of randomization until the date of discharge, assessed up to 6 monthsDescription: Time of disappearance of fever in degrees centigrade
Measure: Time of disappearance of fever symptoms Time: From date of randomization until the date of discharge, assessed up to 6 monthsDescription: The rate of conversion from COVID-19 positive to COVID-19 negative
Measure: The rate of conversion from COVID-19 positive to COVID-19 negative Time: From date of randomization until the date of discharge, assessed up to 6 months.Description: Time of disappearance of cough in times per day
Measure: Time of disappearance of cough Time: From date of randomization until the date of discharge, assessed up to 6 monthsDescription: Respiratory rate in times/minute with blood gas analysis
Measure: Respiratory rate Time: 1-14 days after treatmentDescription: Blood oxygen saturation in percent with blood gas analysis
Measure: Blood oxygen saturation Time: 1-14 days after treatmentDescription: PaO2 in kPa with blood gas analysis
Measure: PaO2 Time: 1-14 days after treatmentDescription: PaCO2 in kPa with blood gas analysis
Measure: PaCO2 Time: 1-14 days after treatmentDescription: The time in days of patients of obvious improvement as shown on chest CT scans relative to admission
Measure: The time of obvious improvement as shown on chest CT scans relative to admission Time: From date of randomization until the date of discharge, assessed up to 6 monthsDescription: The rate in percentages of patients of obvious improvement as shown on chest CT scans relative to admission
Measure: The rate of obvious improvement as shown on chest CT scans relative to admission Time: From date of randomization until the date of discharge, assessed up to 6 monthsDescription: Levels of C-reactive protein measurement in mg/L
Measure: Levels of C-reactive protein Time: 1-14 days after treatmentDescription: Erythrocyte sedimentation rate in mm/h
Measure: Erythrocyte sedimentation rate Time: 1-14 days after treatmentDescription: Levels of Procalcitonin in ng/mL
Measure: Levels of Procalcitonin Time: 1-14 days after treatmentDescription: Serum Levels of interleukin-6 in ng/L
Measure: Levels of interleukin-6 Time: 1-14 days after treatmentDescription: Levels of interleukin-10 in ng/L
Measure: Levels of interleukin-10 Time: 1-14 days after treatmentDescription: Levels of tumor necrosis factor-alpha in ng/mL
Measure: Levels of tumor necrosis factor-alpha Time: 1-14 days after treatmentDescription: Ultrasound examination of the kidney, ureter, and bladder after treatment to mainly check for urolithiasis
Measure: Ultrasound examination of the urinary system Time: 1-14 days after treatmentAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports